CFD
CORT icon

Creative Financial Designs’s Corcept Therapeutics CORT Stock Holding History

Creative Financial Designs’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-901
Closed -$17K – 710
2017
Q3 		$17K Hold
901
– – 0.01% 352
2017
Q2 		$11K Hold
901
– – 0.01% 397
2017
Q1 		$10K Hold
901
– – 0.01% 396
2016
Q4 		$7K Buy
+901
New +$7.06K 0.01% 432

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Creative Financial Designs's CORT Position: Q4 2017 in Review

Creative Financial Designs sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 901 shares — an estimated $17K sold.

Creative Financial Designs first reported a position in CORT in Q4 2016 and held it in 4 quarters. The position peaked at $17K in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • Creative Financial Designs reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Creative Financial Designs sold 901 Corcept Therapeutics shares in Q4 2017, an estimated $17K.
  • Creative Financial Designs first reported a position in Corcept Therapeutics in Q4 2016 and held it in 4 quarters.
  • Creative Financial Designs's Corcept Therapeutics position peaked at $17K in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Creative Financial Designs's 13F filing for Q4 2017, filed 2 May 2018.